34218-97-8

Basic information

• Product Name: epitheaflavic acid 3'-monogallate
• Synonyms: epitheaflavic acid 3'-monogallate
• CAS NO: 34218-97-8
• Molecular Weight: 580.458
• Mol File: 34218-97-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: epitheaflavic acid 3'-monogallate(CAS DataBase Reference)
• NIST Chemistry Reference: epitheaflavic acid 3'-monogallate(34218-97-8)
• EPA Substance Registry System: epitheaflavic acid 3'-monogallate(34218-97-8)

Safety Data

• Hazardous Substances Data: 34218-97-8(Hazardous Substances Data)

Upstream product

• 149-91-7 3,4,5-trihydroxybenzoic acid 
• 863-03-6 (-)-epicatechin gallate 

Relevant articles and documents

ANTI-OBESITY AGENT COMPRISING COMPOUND CONTAINING BENZOTROPOLONE RING

The object of the present invention is to provide an anti-obesity agent which contains a tea-derived component and which is safe and does not compromise the flavor of foods and beverages. According to the present invention, a safe and palatable anti-obesity agent can be provided by incorporating a benzotropolone ring-containing compound which has tea-derived, high inhibitory activities against lipase and alfa-glucosidase. The anti-obesity agent of the present invention does not compromise the flavor of foods and beverage, has palatability, and can be used in various use applications including foods and beverages intended for health enhancement such as reduction in triglycerides.

Enzymatic synthesis of tea theaflavin derivatives and their anti-inflammatory and cytotoxic activities

Derivatives based on a benzotropolone skeleton (9-26) have been prepared by the enzymatic coupling (horseradish peroxidase/H2O2) of selected pairs of compounds (1-8), one with a vic-trihydroxyphenyl moiety, and the other with an ortho-dihydroxyphenyl structure. Some of these compounds have been found to inhibit TPA-induced mice ear edema, nitric oxide (NO) synthesis, and arachidonic acid release by LPS-stimulated RAW 264.7 cells. Their cytotoxic activites against KYSE 150 and 510 human esophageal squamous cell carcinoma and HT 29 human colon cancer cells were also evaluated.